Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours [Phase 1]

View source ↗

Summary

Phase 1 study evaluating AVA6000 in solid tumors, assessing safety, pharmacokinetics, and early efficacy; recruitment is ongoing across several tumor types.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Salivary Gland Cancer
• Soft Tissue Sarcoma
• Urothelial Carcinoma

Drugs mentioned

• AVA6000

Snippet

Sponsor: Avacta Life Sciences Ltd | Conditions: Salivary Gland Tumor, Urothelial Carcinoma | Phase 1 | Status: RECRUITING